ADC Therapeutics SA (NYSE:ADCT) Q4 2022 Earnings Call Transcript

Mohamed Zaki: Thanks for the question. We expect enrollment of 350 patients to be completed next year. There will not be an interim analysis for the study, it’s not built in the protocol. And we’ll update when we get closer to the end of the study.

Ameet Mallik: Yes. And obviously, any time lines post the enrollment depends — it’s an event-driven study. So, in some ways, the longer close to peers, but it also depends on events. Once we complete enrollment and the study starts reading out, we’ll share information.

Operator: Thank you. We have no further questions at this time. I’d now like to turn it back to Ameet for closing remarks.

Ameet Mallik: Well, thank you all for joining so much the webcast, and thanks for all the thoughtful questions. we’re really excited about our ability to unlock the value of this company by maximizing ZYNLONTA, by advancing our PBD-based pipeline and by expanding our ADC platform. We have multiple value-driving catalysts over the next 12 to 18 months, and we look forward to continuing to update you on our progress. Thank you so much for joining.

Operator: Thank you for your participation in today’s conference. This concludes the program. You may now disconnect.